X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-05-25 | ANNX | Bain Capital Life Sciences Investors, LLC | 10% | P - Purchase | $2.13 | +300,000 | 5,701,926 | +6% | +$639,720 | ||||||
2023-02-15 | ANNX | Love Douglas | Pres, CEO | S - Sale | $5.87 | -6,571 | 197,646 | -3% | -$38,564 | ||||||
| M | 2023-02-13 | ANNX | Overdorf Michael | EVP, Chief Business Officer | S - Sale | $6.30 | -1,645 | 27,805 | -6% | -$10,368 | |||||
| M | 2023-02-13 | ANNX | Lew Jennifer | EVP, CFO | S - Sale | $6.31 | -1,908 | 29,542 | -6% | -$12,035 | |||||
2023-02-10 | ANNX | Satter Muneer A | Dir, 10% | P - Purchase | $6.80 | +2,647,058 | 7,056,024 | +60% | +$17,999,994 | ||||||
| D | 2022-07-07 | ANNX | Satter Muneer A | Dir | P - Purchase | $3.84 | +2,453,988 | 4,408,966 | +126% | +$9,423,314 | |||||
2022-04-14 | ANNX | Love Douglas | Pres, CEO | P - Purchase | $2.45 | +60,000 | 200,942 | +43% | +$146,814 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |